Meta‐Analyses on the Effects of Disease‐Modifying Antirheumatic Drugs on the Most Relevant Patient‐Reported Outcome Domains in Rheumatoid Arthritis
Authors' conclusion
DMARDs decrease the burden in all the domains that are relevant to patients.
Study context
- Population
- RCTs in RA reporting patient-reported outcomes of the ICHOM standard set for inflammatory arthritis69 records · 52 studies
- Comparison
- Disease-modifying antirheumatic drugs (DMARDs) vs placebo or MTX
- Outcome
- Patient-reported pain, fatigue and activity limitation (SMD of change scores)
Methodological detailsrandom effects meta-analyses, SMD of change scores
- Random effects meta-analyses
- SMD of change scores
Pooled result
As reported in the abstract
Pain, fatigue and activity limitation, SMD
Estimate (95% CI)
DMARDsvs Placebo
SMD (pain) −0.80(−0.99 to −0.61)
DMARDsvs Placebo
SMD (fatigue) −0.48(−0.64 to −0.32)
DMARDsvs MTX
SMD (pain) −0.55(−0.70 to −0.41)
DMARDsvs MTX
SMD (fatigue) −0.44(−0.55 to −0.33)
DMARDsvs MTX
SMD (activity limitation) - 0.37(−0.44 to −0.30)
- DMARDs vs Placebo
- SMD (activity limitation) −0.56 (95% CI - 0.63, −0.49)
Original publication
Meta‐Analyses on the Effects of Disease‐Modifying Antirheumatic Drugs on the Most Relevant Patient‐Reported Outcome Domains in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). Published 22 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →